Amicus Therapeutics Stock News

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Director Margaret G. Mcglynn sold 10,000 shares of the business’s stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $

Assenagon Asset Management S.A. raised its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 76.1% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 1

Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO John F. Crowley sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price o

Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level.

Leaked report said no S Pen included in the device.

Norges Bank bought a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm boug

If you're interested in Amicus Therapeutics, Inc. (NASDAQ:FOLD), then you might want to consider its beta (a measure...

Bitcoin adoption, something that has somewhat stagnated after a burst of activity following bitcoin's epic 2017 rally, is about to get a boost from a surprising source—U.S. credit card giant Visa...

Geode Capital Management LLC raised its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 4.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange C

Amicus Therapeutics, Inc. (NASDAQ:FOLD) COO Bradley L. Campbell sold 2,500 shares of the business’s stock in a transaction dated Tuesday, April 7th. The shares were sold at an average price of $10.1

Bank of America Corp DE cut its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 69.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Co

On Thursday, April 9th, Fold unveiled the new Fold Card, which the company hailed as the "first bitcoin rewards card."